Storia in 2 fonti

Europe will accelerate its review of RevMed's drug

Kailera's GLP-1 pill data raises concerns, FDA clears Vera autoimmune therapy, and more biotech news from The Readout

Raccontata da

statnews.com

fiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mese fa

Europe will accelerate its review of RevMed's drug

Kailera's GLP-1 pill data raises concerns, FDA clears Vera autoimmune therapy, and more biotech news from The Readout

originale

fiercepharma.com1 mese fa

Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials

In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with CSPC Pharmaceutical and Sino Biopharmaceutical, Hengrui Pharma's Kal | AstraZeneca signed…

Leggi questa versione → originale

Timeline cronologica

mercoledì 8 luglio 2026·statnews.com
Europe will accelerate its review of RevMed's drug
Kailera's GLP-1 pill data raises concerns, FDA clears Vera autoimmune therapy, and more biotech news from The Readout
venerdì 10 luglio 2026·fiercepharma.com
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with CSPC Pharmaceutical and Sino Biopharmaceutical,…